Verona Pharma Plc ADR (NASDAQ:VRNA)’s traded shares stood at 0.86 million during the last session, with the company’s beta value hitting 0.17. At the close of trading, the stock’s price was $75.06, to imply an increase of 3.26% or $2.37 in intraday trading. The VRNA share’s 52-week high remains $75.60, putting it -0.72% down since that peak but still an impressive 84.83% since price per share fell to its 52-week low of $11.39.
Analysts have given a consensus recommendation of Buy for Verona Pharma Plc ADR (VRNA), translating to a mean rating of 1.00. Of 7 analyst(s) looking at the stock, 0 analyst(s) give VRNA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 7 recommend it as a Buy.
Verona Pharma Plc ADR (NASDAQ:VRNA) trade information
After registering a 3.26% upside in the last session, Verona Pharma Plc ADR (VRNA) has traded red over the past five days. The 5-day price performance for the stock is 5.26%, and 15.87% over 30 days. With these gigs, the year-to-date price performance is 61.63%.
The extremes give us $74 and $83 for target low and target high price respectively. As such, VRNA has been trading -10.58% off suggested target high and 1.41% from its likely low.
VRNA Dividends
Verona Pharma Plc ADR has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is MORGAN STANLEY with 0.86 million shares, or about 1.0663% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $12.49 million.
We also have MUTUAL FUND SERIES TRUST-Eventide Gilead Fund and MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund as the top two Mutual Funds with the largest holdings of the Verona Pharma Plc ADR (VRNA) shares. Going by data provided on Dec 31, 2024 , MUTUAL FUND SERIES TRUST-Eventide Gilead Fund holds roughly 1.89 shares. This is just over 2.22% of the total shares, with a market valuation of $141.84 million. Data from the same date shows that the other fund manager holds a little less at 1.23, or 1.44% of the shares, all valued at about 92.32 million.
